Heart Cell Cleanup May Help or Harm During Doxorubicin Treatment
A review explains why boosting cellular cleanup could protect—or further damage—the heart during chemotherapy, depending on whether disposal finishes.
Summary
Doxorubicin treats many cancers but can damage the heart. This review examines how heart cells remove damaged energy-producing structures and parts of their internal protein-processing system. The central message is that increasing cellular cleanup is not automatically protective: too little activity, excessive activity, or a blocked disposal process may contribute to injury. Outcomes depend on the chemotherapy dose, exposure duration, and whether cells can finish breaking down damaged material. Evidence for cleanup of the protein-processing system is especially limited and differs between experimental models. Future treatments may need to restore balanced, complete disposal rather than simply activate or block these pathways. Most evidence comes from cells and animals, not patients. The findings do not establish a preventive treatment or justify changing cancer therapy. This summary is based on the abstract only.
Detailed Summary
Doxorubicin helps treat many cancers, but it can also damage the heart, sometimes leading to abnormal rhythms or heart failure. Understanding how heart cells handle damaged internal machinery could help researchers develop treatments that protect cardiac function without weakening cancer therapy. This review examines two cellular cleanup processes that may influence that balance.
Mitophagy removes damaged mitochondria, the structures that supply much of a cell's energy. A related process, called ER-phagy, removes damaged portions of the endoplasmic reticulum, which helps process proteins and regulate calcium. The authors reviewed evidence on these pathways in doxorubicin heart injury, emphasizing conflicting findings, communication between organelles, and obstacles to translating laboratory results into treatments.
The central finding is that more cleanup is not necessarily better. Mitochondrial clearance may protect cells when damaged material is successfully broken down. However, inadequate activation, excessive activation, or blocked degradation may accompany worse injury. These differences depend on drug dose, exposure duration, and the cell's capacity to finish disposal. Evidence for ER-phagy is more limited and varies between experimental models.
In chronic dosing models, a receptor called CCPG1 has been linked to protective ER-phagy. Acute high-dose models instead show injury-related signals associated with another receptor, FAM134B. Contact sites between mitochondria and the endoplasmic reticulum may coordinate these pathways through calcium exchange and cleanup machinery. Future strategies may need to preserve complete waste removal rather than simply switch either process on or off.
These findings identify research directions, not proven ways for patients to prevent chemotherapy-related heart damage. Most supporting evidence comes from cells and animals. Human heart tissue studies and confirmation that treatments reach their intended cardiac targets are still needed. Any protective approach must also preserve anticancer activity. This summary is based on the abstract only; the review's detailed methods and underlying study quality could not be assessed.
Key Findings
- Mitophagy can protect or harm heart cells depending on doxorubicin exposure and whether damaged material is fully degraded.
- Limited ER-phagy evidence links CCPG1 to protection in chronic models and FAM134B-associated signals to injury in acute high-dose models.
- Researchers should assess completed cellular disposal, not just cleanup activation, when evaluating potential heart-protective treatments.
- Human validation and preservation of anticancer efficacy are essential before translating these pathways into clinical interventions.
Methodology
This mechanistic review synthesizes evidence on mitophagy, ER-phagy, and their potential interactions in doxorubicin-induced cardiotoxicity, largely from cell and animal studies. The abstract does not report a systematic search strategy, study counts, or pooled effect estimates.
Study Limitations
This summary is based on the abstract only; the full review and its assessment of underlying study quality were unavailable. Most evidence is preclinical, direct ER-phagy evidence is limited, and findings vary with experimental dose and timing. Human cardiac target engagement and preservation of antitumor efficacy remain unconfirmed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: